S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Comfytemp Launches Smart Cold Therapy System for Home Recovery

As surgical recovery shifts from hospital wards to living rooms, Comfytemp has introduced the K91C1 Smart Cold Therapy System. Designed to replace the limitations of traditional ice packs, the device offers patients recovering from orthopedic procedures a more consistent, automated method for managing post-operative swelling and pain at home.

Comfytemp Launches Smart Cold Therapy System for Home Recovery
Photo: Bio & News

Traditional methods for post-surgery cooling often force patients with limited mobility to frequently replace melting ice or struggle with cumbersome equipment. The new K91C1 system addresses these logistical hurdles through a 9.5-quart reservoir that provides up to 12 hours of continuous cooling. By incorporating a wireless remote and real-time temperature monitoring, the device allows users to manage their rehabilitation cycles without the physical strain of manual adjustments.

Beyond basic cooling, the system features six adjustable flow settings and programmable timers, catering to recovery protocols for procedures like ACL reconstruction, meniscus repair, and knee replacements. The unit is engineered for quiet operation, intended for use during both daytime activity and sleep. By positioning the product as FSA/HSA eligible, the brand aims to bridge the gap between clinical-grade medical technology and accessible consumer wellness tools, reflecting a broader market trend toward home-based healthcare.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!